Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer |
| |
| Affiliation: | 1. INSERM Unit 981 - Molecular predictors and new targets in oncology, Gustave Roussy, Villejuif, France;2. Univesità Degli Studi di Pavia, Pavia, Italy;3. Unicancer, Paris, France;4. Centre Georges-François Leclerc, Dijon, France;5. Institut Curie, Paris, France;6. Centre Alexis Vautrin, Vandoeuvre Les Nancy, France;7. Institut Curie, Saint Cloud, France;8. Centre Léon Berard, Lyon, France;9. Centre Oscar Lambret, Lille, France;10. Institut Jean Godinot, Reims, France;11. Centre François Baclesse, Caen, France;12. Centre Henri Becquerel, Rouen, France;13. Institut Bergonié, Bordeaux, France |
| |
| Abstract: | We assessed long-term associations of Granulocyte-Colony Stimulating Factors (G-CSF) use with patient-reported outcomes (PROs) and hematologic toxicity among chemotherapy-treated, early-stage breast cancer patients in CANTO (NCT01993498).Among 2920 patients longitudinally followed-up until year-4 after diagnosis, 49% used G-CSF. In multivariable-adjusted mixed-models, EORTC QLQ-C30 pain and summary score were not substantially different between groups (overall adjusted mean difference, use vs no-use [95%CI]: +1.27 [-0.33 to +2.87] and −1.01 [-1.98 to −0.04], respectively). PROs were slightly worse at year-4 among patients receiving G-CSF, although differences were of trivial clinical significance. No major differences were observed in leukocyte or platelet count over time. |
| |
| Keywords: | Breast cancer Survivorship Granulocyte-colony stimulating factors Health-related quality-of-life Patient-reported outcomes |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
